Biotech Defense Act
- Sponsor
- Rep. Biggs, Sheri [R-SC-3]
- Committees
- Intelligence (Permanent Select) Committee (primary)
- Last action
- Oct 22, 2026
Bottom line
The bill aims to proactively safeguard U.S. national security and military superiority by addressing the strategic threats posed by foreign adversaries', especially China's, advancements in dual-use biotechnology through defense planning, intelligence assessments, and investment oversight.
What it actually does
This bill mandates the Secretary of Defense to develop a comprehensive strategy for integrating threats from foreign adversaries' biotechnology capabilities, particularly those of the People's Republic of China, into the National Defense Strategy and Defense Planning Guidance. It also requires the Director of National Intelligence to conduct an assessment of China's military biotechnology advancements and establishes an interagency Biotechnology Risk Contact Group to monitor foreign investments in the U.S. biotechnology sector.
Proponents argue
Proponents argue that the rapid advancement of China in biotechnology, including gene-editing and synthetic biology, combined with its military-civil fusion strategy, poses an existential threat to U.S. national security and military superiority. They contend that this bill is essential for the United States to proactively integrate these threats into defense planning, secure critical biotechnology supply chains, and protect sensitive technologies and data from adversarial exploitation, thereby maintaining a strategic advantage.
Opponents contend
Opponents might express concerns that the bill's focus on securitizing biotechnology could inadvertently stifle innovation, deter legitimate foreign investment, and impede international scientific collaboration, which are crucial for U.S. leadership in the field. They might also argue that an overly broad approach to identifying 'dual-use' technologies or 'foreign adversaries' could lead to unnecessary bureaucratic hurdles and potential overreach in intelligence gathering, without clear benefits.
The bill is concise and straightforward, allowing for a quick read and ample time to evaluate its implications.
Section 1
Short Title
This section formally designates the Act as the 'Biotech Defense Act.' This provides a concise and official name for the legislation, facilitating easy reference and discussion in public and legislative contexts. It is a standard component of most legislative acts.
Supporters argue
Supporters argue that a clear and memorable short title helps in communicating the bill's purpose and facilitates public and legislative discourse around its objectives.
Critics contend
No specific opposition is typically raised against this provision, as it is a standard procedural element of legislation.
Tradeoffs
None. This provision is purely administrative.
Section 2(a)
Sense of Congress on China's Biotechnology Threats
This section articulates Congress's formal opinion that China's rapid advancements in biotechnology, including gene-editing and synthetic biology, combined with its military-civil fusion strategy, pose a significant threat to U.S. national security and military superiority. It highlights risks such as the development of enhanced soldier capabilities, bioweapons, supply chain dominance, and the need for robust oversight of foreign investments in the U.S. biotechnology sector.
Section 2(b), adding new section 118d to title 10, United States Code.
DoD Strategy for Biotechnology Threats
This provision mandates the Secretary of Defense to develop a comprehensive strategy to integrate threats from foreign adversaries' biotechnology capabilities, particularly China's, into the National Defense Strategy and Defense Planning Guidance. The strategy must include assessments of adversaries' military and dual-use biotech, plans to counter these threats through U.S. R&D and supply chain resilience, and coordination with allies. It also requires consultation with various federal agencies, defense and technology industry partners, and research organizations.
Section 2(c)
Intelligence Assessment of China's Military Biotechnology
This section requires the Director of National Intelligence (DNI), in consultation with the CIA, Secretaries of Commerce and Defense, to submit a comprehensive assessment within 180 days of the bill's enactment. This assessment must evaluate China's biotechnology R&D with military applications, analyze its military-civil fusion strategy, assess the potential for bioweapons development, identify Chinese entities involved in dual-use biotech, evaluate China's control over biotech supply chains, and recommend countermeasures. The assessment will be submitted to Congress in unclassified form with a classified annex.
Section 2(d)
Establishment of Biotechnology Risk Contact Group
This provision mandates the Secretary of Defense, in consultation with the Secretaries of State, Commerce, and Treasury, and other federal agencies, to establish a 'Biotechnology Risk Contact Group' within 180 days. This group will monitor and assess foreign investments, partnerships, and joint ventures in the U.S. biotechnology sector, specifically focusing on entities from the People's Republic of China. Its duties include identifying national security risks, coordinating with the Committee on Foreign Investment in the United States (CFIUS), maintaining a database of foreign entities, and providing annual reports to Congress with mitigation recommendations. Regular briefings to Congress are also required.